Non-invasive monitoring of kidney allograft rejection through IDO metabolism evaluation

Kidney International

Volumn 71, Issue 1, 2007, Pages 60-67

  Brandacher, G ^a   Cakar, F ^a   Winkler, C ^a   Schneeberger, S ^a   Obrist, P ^b   Bosmuller C ^a   Werner Felmayer, G ^a   Werner, E R ^a   Bonatti, H ^a   Margreiter, R ^a   Fuchs, D ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

Author keywords

Acute allograft rejection; Renal transplantation; Tolerance

Indexed keywords

GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; NEOPTERIN; TRYPTOPHAN;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; CALCULATION; CLINICAL ARTICLE; ENZYME DEGRADATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY GRAFT; KIDNEY METABOLISM; KIDNEY TRANSPLANTATION; MALE; NON INVASIVE PROCEDURE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; UPREGULATION;

ACUTE DISEASE; ADULT; AGED; CREATININE; EPITHELIAL CELLS; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KIDNEY; KIDNEY TRANSPLANTATION; KYNURENINE; MALE; MIDDLE AGED; NEOPTERIN; TRYPTOPHAN;

EID: 33845694341     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002023     Document Type: Article

References (44)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378-383.
2. Benfield MR, Herrin J, Feld L et al. Safety of kidney biopsy in pediatric transplantation: a report of the Controlled Clinical Trials in Pediatric Transplantation Trial of Induction Therapy Study Group. Transplantation 1999; 67: 544-547.
3. Lechler RI, Sykes M, Thomson AW, Turka LA. Organ transplantation-how much of the promise has been realized? Nat Med 2005; 11: 605-613.
4. Matthews JB, Ramos E, Bluestone JA. Clinical trials of transplant tolerance: slow but steady progress. Am J Transplant 2003; 3: 794-803.
5. Byrne GI, Lehmann LK, Kirschbaum JG et al. Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity. J Interferon Res 1986; 6: 389-396.
6. Pfefferkorn ER. Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sci USA 1984; 81: 908-912.
7. Ozaki Y, Edelstein MP, Duch DS. Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon gamma. Proc Natl Acad Sci USA 1988; 85: 1242-1246.
8. Hwu P, Du MX, Lapointe R et al. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 2000; 164: 3596-3599.
9. Munn DH, Zhou M, Attwood JT et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281: 1191-1193.
10. Mellor AL, Munn DH. Tryptophan catabolism and regulation of adaptive immunity. J Immunol 2003; 170: 5809-5813.
11. Munn DH, Shafizadeh E, Attwood JT et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999; 189: 1363-1372.
12. Fallarino F, Grohmann U, Hwang KW et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003; 4: 1206-1212.
13. Miki T, Sun H, Lee Y et al. Blockade of tryptophan catabolism prevents spontaneous tolerogenicity of liver allografts. Transplant Proc 2001; 33: 129-130.
14. Alexander AM, Crawford M, Bertera S et al. Indoleamine 2,3-dioxygenase expression in transplanted NOD islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes. Diabetes 2002; 51: 356-365.
15. Wirleitner B, Neurauter G, Schrocksnadel K et al. Interferon-gamma- induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Med Chem 2003; 10: 1581-1591.
16. Fuchs D, Möller AA, Reibnegger G et al. Decreased serum tryptophan in patients with HIV-1 infection correlates with increased neopterin and with neurologic/psychiatric symptoms. J Acquir Immune Defic Syndr 1990; 3: 873-876.
17. Weiss G, Murr C, Zoller H et al. Modulation of neopterin formation and tryptophan degradation by Th1- and Th2-derived cytokines in human monocytic cells. Clin Exp Immunol 1999; 116: 435-440.
18. Fuchs D, Weiss G, Reibnegger G, Wachter H. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious and malignant diseases. Crit Rev Clin Lab Sci 1992; 29: 307-341.
19. Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metab 2002; 3: 175-187.
20. Widner B, Werner ER, Schennach H et al. Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem 1997; 43: 2424-2426.
21. Fuchs D, Forsman A, Hagberg L et al. Immune activation and decreased tryptophan in patients with HIV-1 infection. J Interferon Res 1990; 10: 599-603.
22. Huang A, Fuchs D, Widner B et al. Tryptophan decrease in advanced colorectal cancer correlates with immune activation and impaired quality of life. Br J Cancer 2002; 86: 1691-1696.
23. Wirleitner B, Rudzite V, Neurauter G et al. Immune activation and degradation of tryptophan in coronary heart disease. Eur J Clin Invest 2003; 33: 550-554.
24. Widner B, Leblhuber F, Walli J et al. Tryptophan degradation and immune activation in Alzheimer's disease. J Neural Transm 2000; 107: 343-353.
25. Widner B, Sepp N, Kowald E et al. Enhanced tryptophan degradation in systemic lupus erythematosus. Immunobiology 2000; 201: 621-630.
26. Schroecksnadel K, Winkler C, Fuith LC, Fuchs D. Tryptophan degradation in patients with gynecological cancer correlates with immune activation. Cancer Lett 2005; 223: 323-329.
27. Beckingham IJ, Nicholson ML, Bell PR. Analysis of factors associated with complications following renal transplant needle core biopsy. Br J Urol 1994; 73: 13-15.
28. Nicholson ML, Wheatley TJ, Doughman TM et al. A prospective randomized trial of three different sizes of core-cutting needle for renal transplant biopsy. Kidney Int 2000; 58: 390-395.
29. Rosenberg AS, Singer A. Cellular basis of skin allograft rejection: an in vivo model of immune-mediated tissue destruction. Annu Rev Immunol 1992; 10: 333-358.
30. Koga S, Auerbach MB, Engeman TM et al. T cell infiltration into class II MHC-disparate allografts and acute rejection is dependent on the IFN-gamma-induced chemokine Mig. J Immunol 1999; 163: 4878-4885.
31. Hernandez-Fuentes MP, Salama A. In vitro assays for immune monitoring in transplantation. Methods Mol Biol 2006; 333: 269-290.
32. Muthukumar T, Dadhania D, Ding R et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005; 353: 2342-2351.
33. Weimer R, Süsal C, Yildiz S et al. Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens. Am J Transplant 2006; 6: 1865-1874.
34. Sadeghi M, Daniel V, Naujokat C et al. Association of high pretransplant sIL-6R plasma levels with acute tubular necrosis in kidney graft recipients. Transplantation 2006; 81: 1716-1724.
35. Reibnegger G, Aichberger C, Fuchs D et al. Posttransplant neopterin excretion in renal allograft recipients - a reliable diagnostic aid for acute rejection and a predictive marker of long-term graft survival. Transplantation 1991; 52: 58-63.
36. Aulitzky WE, Tilg H, Niederwieser D et al. Comparison of serum neopterin levels and urinary neopterin excretion in renal allograft recipients. Clin Nephrol 1988; 29: 248-252.
37. Holmes EW, Russell PM, Kinzler GJ et al. Oxidative tryptophan metabolism in renal allograft recipients: increased kynurenine synthesis is associated with inflammation and OKT3 therapy. Cytokine 1992; 4: 205-213.
38. Baban B, Hansen AM, Chandler PR et al. A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Int Immunol 2005; 17: 909-919.
39. Werner ER, Bitterlich G, Fuchs D et al. Human macrophages degrade tryptophan upon induction by interferon-gamma. Life Sci 1987; 41: 273-280.
40. Sakurai K, Zou JP, Torres NI et al. Study of the effect of indoleamine 2,3-dioxygenase on murine mixed lymphocyte reactions and skin allograft rejection. Transplant Proc 2002; 34: 3271-3273.
41. Grohmann U, Orabona C, Fallarino F et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002; 3: 1097-1101.
42. Vincenti F, Larsen C, Durrbach A et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770-781.
43. Swanson KA, Zheng Y, Heidler KM et al. CDllc+ cells modulate pulmonary immune responses by production of indoleamine 2,3-dioxygenase. Am J Respir Cell Mol Biol 2004; 30: 311-318.
44. Gastl G, Spizzo G, Obrist P et al. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 2000; 356: 1981-1982.